Cary G. Vance, Chief Executive Officer
Cary G. Vance was appointed as President and Chief Executive Officer at OptiScan Biomedical on May 21, 2018. Mr. Vance has extensive leadership experience and a record of consistent achievement in transforming businesses and driving sustained growth for over 30 years. He previously served as President and Chief Executive Officer at Myoscience Incorporated, where he led the company in a turnaround effort towards unprecedented growth and profitability, strategically transforming the business and their markets with disruptive technology. He also served as President and Chief Executive Officer at Hansen Medical for over two years, where he led a turnaround effort that resulted in the successful sale of the company. Prior to Hansen, Mr. Vance served as President of the Anesthesia & Respiratory global business at Teleflex Incorporated and as their Executive Vice President North America. Before joining Teleflex, he was an executive at Covidien, and served as Vice President & General Manager of Interventional Oncology – Americas, and was the Vice President & General Manager for their Energy-based Devices unit for three years. Mr. Vance served in a series of roles with progressive responsibility at GE Healthcare from 1997 to 2007, principally in diagnostic imaging sales and marketing management, and executive leadership. Mr. Vance is Lean/Six Sigma Black Belt certified, and holds a B.A. in Economics and an M.B.A from Marquette University.
Patrick Nugent, Chief Financial Officer
Patrick Nugent is the CFO at OptiScan Biomedical. Mr. Nugent has over 16 years of extensive experience in raising capital, strategic and financial planning, audits and investor relations. Prior to joining OptiScan Biomedical, Mr. Nugent held the position of Chief Financial Officer at Pelikan Technologies Inc. Before that Mr. Nugent held the position of Chief Financial Officer and Executive Vice President of Finance for Telesensory Corporation for worldwide operations. Mr. Nugent has a bachelor’s degree in Accounting and Financial Management and is a Chartered Management Accountant from the Chartered Institute of Management Accountants of London, England.
Jim Causey, VP of Innovation
Jim Causey has been the VP, Research & Development of OptiScan since 2012. From 2005 to 2007, Mr. Causey was CEO of M2 Medical Technologies, a medical device start-up developing a next generation insulin pump. Directly prior to joining OptiScan, Mr. Causey had established his own consulting firm.
Mr. Causey was VP of Research & Development at MiniMed Inc. from 1997-2001, responsible for the development of MiniMed’s insulin pump products. While at MiniMed, he led the effort to introduce the most successful insulin pump in MiniMed’s history, either before or after the subsequent acquisition by Medtronic, Inc. Mr. Causey began his career at Pacesetter Systems in 1981, where he participated in and led the development of implantable pacemakers over a period of 15 years. Pacesetter was later acquired by St. Jude Medical. After that acquisition, Mr. Causey held the position of Vice President of Defibrillator Development, leading a team that introduced an industry-leading ICD.
Mr. Causey is a named inventor in over 90 allowed US patents. He has a pre-med Biology degree from CSUN, Northridge, California.
Mario P. Cervantes, VP Operations
Mario P. Cervantes has been driving business success through operational transformations for medical device and consumer electronics manufacturers for over 30 years; leading operations in the US, Mexico and South America and serving customers at worldwide locations. Mr. Cervantes is a visionary, multicultural and global operations leader with experience in all facets of operations. He is known for building excellent teams and implementing continuous improvement systems that drive significant operating margin, quality and customer satisfaction improvements. Mr. Cervantes has worked for medical device companies BD-CareFusion, Teleflex, Covidien and Puritan Bennet; and for Proxima and Bourns in the high-end electronics arena. Most recently, he worked at Mettler Toledo as Head of R&D, Quality and Operations for the Rainin Life Science Lab Instrument Unit. Mr. Cervantes earned his Bachelor’s degree in Electromechanical Engineering from ITESM in Monterrey, MX, with certifications in Lean Management and in Operational Excellence earned at SDSU and at MIT-Sloan.
Chip Zimliki, Vice President of Regulatory, Quality, & Clinical Affairs
Chip Zimliki, Ph.D. is VP of Regulatory, Quality, and Clinical Affairs at OptiScan. Dr. Zimliki has over 17 years of experience in global regulatory leadership and strategy. Previously, Dr. Zimliki was at Medtronic Diabetes, serving as the Sr. Director of Regulatory Affairs for the Advanced Insulin Management Business Unit. His global regulatory responsibilities spanned both premarket and postmarket activities across diagnostic and insulin delivery devices. During his tenure at Medtronic Diabetes, Dr. Zimliki worked closely with the FDA in developing the appropriate testing needed for approval of the first Hybrid Closed Loop system in the U.S. and internationally. Prior to Medtronic, Dr. Zimliki worked for the FDA in the Center for Devices and Radiological Health (CDRH) for 9 years. During that time, he served in a number of roles across the Plastic and Reconstructive Surgical Branch (PRSB) and the General Hospital Devices Branch (GHDB), including 510(k) Team leader, Diabetes Team Leader, and Chair of the InterAgency Artificial Pancreas Working Group.
Dr. Zimliki graduated from Virginia Polytechnic Institute and State University with a B.S. in Engineering Science and Mechanics. He received his Ph.D. in Biomedical Engineering from Johns Hopkins University and performed his research at the National Institutes of Health.
OptiScan Biomedical has received CE Mark certification for the OptiScanner 5000/6000 system.